276 related articles for article (PubMed ID: 22689417)
1. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Sendón JL; Lee S; Cheng ML; Ben-Yehuda O;
Eur J Prev Cardiol; 2012 Oct; 19(5):952-9. PubMed ID: 22689417
[TBL] [Abstract][Full Text] [Related]
2. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
3. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman BR
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
6. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Stone PH; Gratsiansky NA; Blokhin A; Huang IZ; Meng L;
J Am Coll Cardiol; 2006 Aug; 48(3):566-75. PubMed ID: 16875985
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Koren MJ; Crager MR; Sweeney M
J Am Coll Cardiol; 2007 Mar; 49(10):1027-34. PubMed ID: 17349881
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
Rousseau MF; Pouleur H; Cocco G; Wolff AA
Am J Cardiol; 2005 Feb; 95(3):311-6. PubMed ID: 15670536
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine (Roche Bioscience).
Jones R
IDrugs; 1999 Dec; 2(12):1353-62. PubMed ID: 16113967
[TBL] [Abstract][Full Text] [Related]
10. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease.
Stone PH; Chaitman BR; Stocke K; Sano J; DeVault A; Koch GG
J Am Coll Cardiol; 2010 Sep; 56(12):934-42. PubMed ID: 20828645
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
12. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine for the treatment of refractory angina in a veterans population.
Greene RS; Rangel RM; Edwards KL; Chastain LM; Brouse SD; Alvarez CA; Collins LJ; Brilakis ES; Banerjee S
Cardiovasc Revasc Med; 2012; 13(2):141.e1-5. PubMed ID: 21856249
[TBL] [Abstract][Full Text] [Related]
15. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine: a new option in the management of chronic stable angina.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Cocco G; Rousseau MF; Bouvy T; Cheron P; Williams G; Detry JM; Pouleur H
J Cardiovasc Pharmacol; 1992 Jul; 20(1):131-8. PubMed ID: 1383622
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine: new drug. Stable angina: not worth the risk.
Prescrire Int; 2009 Aug; 18(102):148-7. PubMed ID: 19743543
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine: an anti-anginal drug with further therapeutic potential.
Reffelmann T; Kloner RA
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):319-29. PubMed ID: 20222810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
